Biopharma company Celladon held a second close on $53 million of financing after previously closing on $43 million in February. MPM Capital and Life Sciences Partners joined the existing investor group to participate in this latest funding. In conjunction, Celladon has added MPM managing director Todd Foley and LSP general partner Fouad Azzam Ph.D. to its Board of Directors.
La Jolla, CA
Developer of molecular therapies for the treatment of heart failure